kabutan

Cyfuse Biomedical K.K.(4892) Summary

4892
TSE Growth
Cyfuse Biomedical K.K.
620
JPY
-10
(-1.59%)
Mar 13, 3:30 pm JST
3.88
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
2.33
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
620 JPY 3.89 USD
Previous Close Mar 12
630 JPY 3.96 USD
High Mar 13, 10:28 am
623 JPY 3.91 USD
Low Mar 13, 9:06 am
612 JPY 3.84 USD
Volume
29,200
Trading Value
0.02B JPY 0.11M USD
VWAP
618.75 JPY 3.88 USD
Minimum Trading Value
62,000 JPY 388 USD
Market Cap
6.18B JPY 0.04B USD
Number of Trades
103
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Slightly High
1-Year Average
455
1-Year High Oct 1, 2025
6,713
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 955,800
Feb 27, 2026 0 975,800
Feb 20, 2026 0 1,005,600
Feb 13, 2026 200 1,048,300 5241.50
Feb 6, 2026 0 1,077,200
Company Profile
Cyfuse Biomedical K.K. engages in the development, manufacturing, and sales of regenerative medicine products using bio 3D printers.
Sector
Pharmaceuticals
Cyfuse Biomedical K.K. primarily focuses on the development, manufacturing, and sales of regenerative medicine products using bio 3D printers, while expanding its multifaceted business across three domains: regenerative medicine, drug discovery support, and devices. In the regenerative medicine field, the company develops new regenerative medicine products by creating three-dimensional tissues and organs made solely from cells, advancing multiple pipelines such as peripheral nerve regeneration and bone and cartilage regeneration. In the drug discovery support area, Cyfuse offers contract research services for cell products and develops and sells new 3D cell products like organ models. In the device domain, the company develops and sells bio 3D printers, applies technologies necessary for cell product development, and creates new technologies. Through its proprietary core technology and strategic partnerships, Cyfuse Biomedical K.K. aims to realize innovative regenerative medicine products.